136 related articles for article (PubMed ID: 20441964)
1. Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins.
Harris LF; Castro-López V; Hammadi N; O'Donnell JS; Killard AJ
Talanta; 2010 Jun; 81(4-5):1725-30. PubMed ID: 20441964
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.
Castro-López V; Harris LF; O'Donnell JS; Killard AJ
Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas.
Harris LF; Castro-López V; Jenkins PV; O'Donnell JS; Killard AJ
Thromb Res; 2011 Dec; 128(6):e125-9. PubMed ID: 21824646
[TBL] [Abstract][Full Text] [Related]
5. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays.
Coppell JA; Thalheimer U; Zambruni A; Triantos CK; Riddell AF; Burroughs AK; Perry DJ
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):97-104. PubMed ID: 16479191
[TBL] [Abstract][Full Text] [Related]
6. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
7. Danaparoid is not a low-molecular-weight heparin.
Nicholson CD; Meuleman DG; Magnani HN; Egberts JF; Leibowitz DA; Spinler SA; Cziraky MJ
Am J Hosp Pharm; 1994 Aug; 51(16):2049-50. PubMed ID: 7526686
[No Abstract] [Full Text] [Related]
8. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
Zmuda K; Neofotistos D; Ts'ao CH
Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
[TBL] [Abstract][Full Text] [Related]
9. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study.
Grassegger A; Fritsch P; Reider N
Dermatol Surg; 2001 Jan; 27(1):47-52. PubMed ID: 11231243
[TBL] [Abstract][Full Text] [Related]
10. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis].
Shen Y; Kang J
Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122
[TBL] [Abstract][Full Text] [Related]
11. Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data.
Hollestelle MJ; van der Meer FJM; Meijer P
Clin Chem Lab Med; 2020 Oct; 58(11):1921-1930. PubMed ID: 32441664
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
Polkinghorne KR; McMahon LP; Becker GJ
Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
[TBL] [Abstract][Full Text] [Related]
13. Heparinoids Danaparoid and Sulodexide as clinically used drugs.
Dou H; Song A; Jia S; Zhang L
Prog Mol Biol Transl Sci; 2019; 163():55-74. PubMed ID: 31030761
[TBL] [Abstract][Full Text] [Related]
14. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.
Burgess JK; Chong BH
Eur J Haematol; 1997 Apr; 58(4):279-85. PubMed ID: 9186540
[TBL] [Abstract][Full Text] [Related]
15. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
16. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
17. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
Olah Z; Szarvas M; Bereczky Z; Kerenyi A; Kappelmayer J; Boda Z
Arch Pathol Lab Med; 2013 Jul; 137(7):967-73. PubMed ID: 23808469
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
[TBL] [Abstract][Full Text] [Related]
19. Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays.
Castro-López V; Harris LF; O'Donnell JS; Killard AJ
J Pharm Biomed Anal; 2011 Dec; 56(5):992-7. PubMed ID: 21852056
[TBL] [Abstract][Full Text] [Related]
20. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems.
Longstaff C; Hogwood J; Gray E; Komorowicz E; Varjú I; Varga Z; Kolev K
Thromb Haemost; 2016 Mar; 115(3):591-9. PubMed ID: 26632486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
